|
Nov 28
|
SciSparc Adopts Limited Duration Shareholder Rights Plan
|
|
Nov 28
|
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
|
|
Nov 27
|
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
|
|
Sep 7
|
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
|
|
Sep 7
|
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
|